Compounds > 3'-c-methyladenosine
Page last updated: 2024-12-08

3'-c-methyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-C-methyladenosine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID493225
CHEMBL ID480143
SCHEMBL ID1066935
MeSH IDM0488189

Synonyms (11)

Synonym
3'-c-methyl ado
(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-3-methyl-tetrahydrofuran-3,4-diol
9-(3'-c-methyl-.beta.-d-ribofuranosyl) adenine
3'-c-methyladenosine
CHEMBL480143 ,
15397-13-4
bdbm50408410
SCHEMBL1066935
(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-2-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol
3'-b-c-methyladenosine
(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-2-(hydroxymethyl)-3-methyloxolane-3,4-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki51.00000.00011.20929.9700AID31854
Adenosine receptor A1Bos taurus (cattle)Ki49.50000.00000.71316.0000AID32002
RNA-directed RNA polymerase IC50 (µMol)50.00000.01902.52798.8000AID86858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)EC50 (µMol)50.00000.00260.53341.2020AID86857
RNA-directed RNA polymerase EC50 (µMol)50.00000.00180.23482.8000AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Bos taurus (cattle)
response to purine-containing compoundAdenosine receptor A1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID247910In vitro inhibitory activity against human leukemia K562IU cell line2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID1168487Growth inhibition of human MCF7 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID595460Antiproliferative activity against human K562 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID244279Percent displacement of [3H]CGS-21680 binding to adenosine A2A receptors of bovine striatal membranes at 0.00005 M2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID33330Inhibitory activity against Adenosine A3 receptor by inhibition of [3H](R)-PIA binding to rat testis membranes1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID248027In vitro inhibitory activity against human colon carcinoma HT-29 cell line2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID1168479Cytotoxicity against human HL60 cells at 20 to 100 uM after 24 to 48 hrs in presence of 2 mM VPA by trypan blue dye exclusion method2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID340156Antitumor activity against human MCF7 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID1168485Growth inhibition of human HUT78 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID248110In vitro inhibitory activity against human myelogenous leukemia K562 cell line2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID1168463Induction of cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 20 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 54%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID595461Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID1168478Induction of apoptosis in human HL60 cells after 24 to 48 hrs by acridine orange and ethidium bromide staining based fluorescence microscopy2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID233378Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID244278Percent displacement of [125I]AB-MECA binding to adenosine A3 receptors of bovine cortical membranes at 0.00005 M2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID33022Ability to displace [3H]-CGS- 21680 from Adenosine A2A receptor of rat brain striatum at 10e-5 M2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID1168467Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G2M phase at 20 uM in presence of 2 mM VPA after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID340153Antitumor activity against human K562 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID32002Inhibitory activity at Adenosine A1 receptor by inhibition of [3H]CHA binding to bovine brain cortical membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID233377Inhibitory selectivity at Adenosine 2A receptor compared to Adenosine 1 receptor.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1168480Cytotoxicity against human HL60 cells at 20 to 100 uM after 24 to 48 hrs in presence of 1 mM VPA by trypan blue dye exclusion method2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168482Induction of apoptosis in human HL60 cells at 20 uM in presence of 1 mM VPA after 24 to 48 hrs by acridine orange and ethidium bromide staining based fluorescence microscopy2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168464Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G2M phase at 20 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID31854Inhibition of [3H]CHA (N6-cyclohexyl adenosine) to rat brain membrane Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID33205Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat Adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID595459Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID86858Inhibition HCV NS5B-mediated RNA synthesis2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1168484Growth inhibition of human K562 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID340154Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID244280Percent displacement of [3H]DPCPX binding to adenosine A1 receptors of bovine cortical membranes at 0.00005 M2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID1168477Cytotoxicity against human HL60 cells after 24 to 48 hrs by trypan blue dye exclusion method2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168483Growth inhibition of human HL60 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID33765Binding affinity determined on Adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID595463Antiproliferative activity against human Caco2 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID33922Inhibitory activity against Adenosine A2A receptor by inhibition of [3H]-CGS- 21680 binding to bovine striatal membranes1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID1168462Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 20 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 32%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168489Growth inhibition of human Caco2 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168481Induction of apoptosis in human HL60 cells at 20 uM in presence of 2 mM VPA after 24 to 48 hrs by acridine orange and ethidium bromide staining based fluorescence microscopy2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID248043In vitro inhibitory activity against human breast carcinoma MCF-7 cell line2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID1168466Induction of cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 20 uM in presence of 2 mM VPA after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 54%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID595462Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID86857Inhibition HCV RNA replication2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1168443Half life in RPMI-1640 medium containing 10% fetal calf serum assessed as compound disappearance by HPLC-DAD-ESI-MS method2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168486Growth inhibition of human HT-29 cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID1168488Growth inhibition of human HeLa cells after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
AID33019Selectivity for Adenosine A2A over Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID33490Selectivity for Adenosine A3 over Adenosine A1 receptor2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID340155Antitumor activity against human HT29 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID1168465Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 20 uM in presence of 2 mM VPA after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 32%)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (20.00)18.2507
2000's5 (50.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
9-xylosyladenine
9-xylosyladenine: RN given refers to cpd with unspecified isomeric designation; structure in first source		1.9810purine nucleoside
3-deazaadenosine
[no description available]		1.9810
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.110branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
hydroxyurea
[no description available]		2.110one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		1.9810antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
cordycepin
[no description available]		2.02103'-deoxyribonucleoside;
adenosines		antimetabolite;
nucleoside antibiotic
2-chloroadenosine
5-chloroformycin A: structure given in first source		2.6930purine nucleoside
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		1.9810purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
6-hydroxyadenosine
[no description available]		2.0610
cladribine
[no description available]		1.9810organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
hyaluronoglucosaminidase
kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source		2.4120purine nucleoside
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.420beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		1.9810
1-methyladenosine
[no description available]		2.0410methyladenosinehuman metabolite
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.0410organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		3.1350adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
aristeromycin
aristeromycin: RN given refers to (1R-(1alpha,2alpha,3beta,5alpha)-isomer		1.9810
metrifudil
[no description available]		1.9810
n(6)-benzyladenosine
N(6)-benzyladenosine: RN given refers to parent cpd		2.4120
phenylisopropyladenosine
[no description available]		2.4120aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
8-bromoadenosine
[no description available]		1.9810purine nucleoside
8-aminoadenosine
[no description available]		1.9810
2'-fluoro-2'-deoxyadenosine
[no description available]		2.0210
n(6)-phenyladenosine
[no description available]		2.0410purine nucleoside
n(6)-methoxyadenosine
[no description available]		2.0610
n-methyladenosine
N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.		2.0210methyladenosine
2'-o-methyladenosine
cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.		2.420adenosines;
ether		fungal metabolite
3'-fluoro-3'-deoxyadenosine
3'-fluoro-3'-deoxyadenosine: structure given in first source		2.0210
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.		2.6930adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
2-chloro-n(6)cyclopentyladenosine
2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors		2.4220
5'-noraristeromycin
5'-noraristeromycin: structure given in first source		1.9810
2-hexynyladenosine-5'-n-ethylcarboxamide
2-hexynyladenosine-5'-N-ethylcarboxamide: adenosine receptor agonist		1.9810
5'-deoxyadenosine
5'-deoxyadenosine: main heading DEOXYADENOSINE refers to the 3' cpd. 5'-deoxyadenosine : A 5'-deoxyribonucleoside compound having adenosine as the nucleobase.		1.98105'-deoxyribonucleoside;
adenosines		Escherichia coli metabolite;
human metabolite;
mouse metabolite
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.0610antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
adenosine-5'-(n-ethylcarboxamide)
Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.		2.6930adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
2'-c-methyladenosine
2'-C-methyladenosine: antiviral		3.2760
fludarabine
[no description available]		1.9810purine nucleoside
n(6)-cyclopentyladenosine
[no description available]		2.730
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source		2.0210
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer
[no description available]		2.4120
1-aminoadenosine
1-aminoadenosine: structure		2.4220
n(6)-cyclohexyladenosine
N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist		2.4220
ribose
ribopyranose : The pyranose form of ribose.		7.0410D-ribose;
ribopyranose
2'-o-methylguanosine
2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.		2.0210methylguanosinemetabolite
2'-deoxy-2'-fluoroguanosine
2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses		2.0210
3-deoxyguanosine
3'-deoxyguanosine : A 3'-deoxyribonucleoside having guanine as the nucleobase.		2.02103'-deoxyribonucleoside;
guanosines		EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Leucocythaemia
[description not available]		02.0610
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0610